Shionogi Inc

FETROJA

Manufacturer:

Shionogi Inc

Fetroja HCPCS:

J0699

HCPCS Code Descriptor:

Injection, cefiderocol, 10 mg

Category:

J Code

Fetroja NDCs:

59630-0266-10

Primary Type:

Antibiotic

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Fetroja:

FETROJA is an Antibiotic drug manufactured by Shionogi Inc and administered via the Intravenous route of administration. The J Code: J0699 is aligned to the drug FETROJA.

Fetroja is an antibacterial drug used to treat infections caused by Gram-negative bacteria, specifically in complicated urinary-tract infections. This medication is administered through intravenous infusion over the course of three hours. Fetroja was previously aligned to the HCPCS code J0693, which was discontinued in October 2021. The new HCPCS code for Fetroja is J0699.

ACCESS PRICING AND MORE BY REGISTERING

J0699 Added Date:

October 1, 2021

J0699 Effective Date:

October 1, 2021

J0699 Termination Date:

HCPCS Active

Fetroja billing and coding information can be found through Shionogi Inc at the link below:
Fetroja patient assistance information can be found through Shionogi at the URL: https://www.fetroja.com/
FETROJA prescribing information can be found at the link below:
Information regarding FETROJA’s side effects can be found at MedlinePlus